Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.98+0.19 (+1.28%)
Close on Nov 18, 2026Market cap $12.50BP/E 27.5Yield 0.57%
Dr Reddys Laboratories operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2026 it was ₹50.55B, down 29.6% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is ₹71.84B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹50.55B | -29.6% |
| FY2025 | Mar 31, 2025 | ₹71.84B | +6.1% |
| FY2024 | Mar 31, 2024 | ₹67.73B | +18.5% |
| FY2023 | Mar 31, 2023 | ₹57.14B | +93.9% |
| FY2022 | Mar 31, 2022 | ₹29.48B | +21.4% |
| FY2021 | Mar 31, 2021 | ₹24.28B | +51.8% |
| FY2020 | Mar 31, 2020 | ₹15.99B | -23.4% |
| FY2019 | Mar 31, 2019 | ₹20.89B | +75.3% |
| FY2018 | Mar 31, 2018 | ₹11.92B | -11.7% |
| FY2017 | Mar 31, 2017 | ₹13.50B | -54.4% |
| FY2016 | Mar 31, 2016 | ₹29.62B | – |
See a number that looks wrong?